Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) was the target of a significant growth in short interest in June. As of June 15th, there was short interest totaling 16,744 shares, a growth of 330.5% from the May 31st total of 3,889 shares. Based on an average trading volume of 2,088 shares, the short-interest ratio is presently 8.0 days. Currently, 9.8% of the shares of the company are short sold.
Amplify Weight Loss Drug & Treatment ETF Stock Performance
NYSEARCA:THNR traded up $0.42 during mid-day trading on Friday, reaching $25.36. 2,062 shares of the company’s stock were exchanged, compared to its average volume of 2,102. Amplify Weight Loss Drug & Treatment ETF has a one year low of $21.70 and a one year high of $27.28. The business’s fifty day simple moving average is $24.50 and its two-hundred day simple moving average is $25.10. The firm has a market capitalization of $4.31 million, a PE ratio of 24.31 and a beta of 0.40.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new position in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned approximately 10.02% of Amplify Weight Loss Drug & Treatment ETF at the end of the most recent reporting period.
About Amplify Weight Loss Drug & Treatment ETF
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
Featured Articles
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
